CD274 and non-small cell lung carcinoma: Furthermore, immune checkpoint inhibitors have significantly prolonged PFS and OS in specific advanced NSCLC patients, due to the assessment of PD1/PDL1 expression and tumor mutation burden (TMB) (5–7).